2023-06-14 11:17:42
The scientists presented the results of the final phase of clinical trials of combined treatment for Hodgkin’s lymphoma, which was received by both adults and adolescents in the last stages of the disease. Now the treatment protocol should be approved as soon as possible for clinical practice.
The study examined the effects of experimental immunotherapy combined with chemotherapy in patients with stage 3 and 4 Hodgkin’s lymphoma, a cancer that affects the organs of the lymphatic system. For the first time, patients over the age of 12 were included in the study. Scientists hoped for an effective result, but the data obtained far exceeded their expectations. Conclusions of the final phase of research published on the University of Rochester website.
The combination of nivolumab and chemotherapy resulted in remission in 94% of patients, which was maintained throughout the follow-up period of one year. The safety of the approach has also been confirmed. Most importantly, long-term safety has been demonstrated in adolescents, who are currently routinely given radiation therapy to fight tumors, but this strategy often results in side effects, including cancer recurrence.
“When we received convincing data, an order was issued to terminate the study early in order to expedite the process of reviewing a new treatment protocol by the regulator for final approval,” the scientists commented. It is not yet clear how long the approval will take, but effective and safe treatment should be available to patients in the very near future.
Previously another drug combination led to similar results in patients with non-Hodgkin’s lymphoma – more than 95% of children were alive and well three years following treatment.
1686847440
#Therapy #cured #patients #Hodgkins #lymphoma
